Osmotica to Present at 9th Annual SVB Leerink Global Healthcare Conference
18 févr. 2020 17h00 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
Osmotica Announces Pricing of Public Offering of Ordinary Shares
08 janv. 2020 20h40 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the...
Osmotica Announces Proposed Public Offering of Ordinary Shares
06 janv. 2020 06h50 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the...
Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Acceptance of New Drug Application by FDA for RVL-1201 (Oxymetazoline Hydrochloride Ophthalmic Solution, 0.1%) for Acquired Blepharoptosis (Droopy Eyelid)
20 nov. 2019 06h50 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated...
Osmotica Pharmaceuticals plc Reports Third Quarter 2019 Results
14 nov. 2019 16h05 HE
|
Osmotica Holdings US LLC
Third quarter 2019 total revenue of $65.5 million Submitted NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, to FDA ...
Osmotica Pharmaceuticals plc to Provide Third Quarter 2019 Business and Financial Update on November 15, 2019
08 nov. 2019 13h00 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the...
Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors
27 sept. 2019 06h50 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced the...
Vertical Pharmaceuticals LLC, an Osmotica company, Announces Presentation of Phase III RVL-1201 Clinical Trial Data in Patients with Acquired Blepharoptosis (droopy eyelid)
18 sept. 2019 06h50 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated...
Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Submission of New Drug Application for RVL-1201
17 sept. 2019 06h50 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated...
Osmotica Pharmaceuticals plc to Present at 2019 Wells Fargo Healthcare Conference
28 août 2019 16h30 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that...